Moleculin Biotech Stock Market Value
| MBRX Stock | USD 2.62 0.03 1.13% |
| Symbol | Moleculin |
Moleculin Biotech Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.04) | Return On Assets (0.57) | Return On Equity (1.41) |
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moleculin Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Moleculin Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Moleculin Biotech's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Moleculin Biotech.
| 10/28/2024 |
| 11/27/2024 |
If you would invest 0.00 in Moleculin Biotech on October 28, 2024 and sell it all today you would earn a total of 0.00 from holding Moleculin Biotech or generate 0.0% return on investment in Moleculin Biotech over 30 days. Moleculin Biotech is related to or competes with Eliem Therapeutics, Scpharmaceuticals, Milestone Pharmaceuticals, Seres Therapeutics, and Lumos Pharma. Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the ... More
Moleculin Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Moleculin Biotech's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Moleculin Biotech upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.67 | |||
| Information Ratio | 0.0314 | |||
| Maximum Drawdown | 35.41 | |||
| Value At Risk | (7.01) | |||
| Potential Upside | 9.75 |
Moleculin Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Moleculin Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Moleculin Biotech's standard deviation. In reality, there are many statistical measures that can use Moleculin Biotech historical prices to predict the future Moleculin Biotech's volatility.| Risk Adjusted Performance | 0.0503 | |||
| Jensen Alpha | 0.3499 | |||
| Total Risk Alpha | (0.57) | |||
| Sortino Ratio | 0.0375 | |||
| Treynor Ratio | (0.62) |
Moleculin Biotech Backtested Returns
Moleculin Biotech appears to be risky, given 3 months investment horizon. Moleculin Biotech has Sharpe Ratio of 0.0354, which conveys that the firm had a 0.0354% return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Moleculin Biotech, which you can use to evaluate the volatility of the firm. Please exercise Moleculin Biotech's Downside Deviation of 4.67, mean deviation of 3.83, and Risk Adjusted Performance of 0.0503 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Moleculin Biotech holds a performance score of 2. The company secures a Beta (Market Risk) of -0.47, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Moleculin Biotech are expected to decrease at a much lower rate. During the bear market, Moleculin Biotech is likely to outperform the market. Please check Moleculin Biotech's maximum drawdown, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Moleculin Biotech's current price movements will revert.
Auto-correlation | -0.19 |
Insignificant reverse predictability
Moleculin Biotech has insignificant reverse predictability. Overlapping area represents the amount of predictability between Moleculin Biotech time series from 28th of October 2024 to 12th of November 2024 and 12th of November 2024 to 27th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Moleculin Biotech price movement. The serial correlation of -0.19 indicates that over 19.0% of current Moleculin Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.19 | |
| Spearman Rank Test | -0.1 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Moleculin Biotech lagged returns against current returns
Autocorrelation, which is Moleculin Biotech stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Moleculin Biotech's stock expected returns. We can calculate the autocorrelation of Moleculin Biotech returns to help us make a trade decision. For example, suppose you find that Moleculin Biotech has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Moleculin Biotech regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Moleculin Biotech stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Moleculin Biotech stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Moleculin Biotech stock over time.
Current vs Lagged Prices |
| Timeline |
Moleculin Biotech Lagged Returns
When evaluating Moleculin Biotech's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Moleculin Biotech stock have on its future price. Moleculin Biotech autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Moleculin Biotech autocorrelation shows the relationship between Moleculin Biotech stock current value and its past values and can show if there is a momentum factor associated with investing in Moleculin Biotech.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.